Literature DB >> 6378370

Interactions of the UVRABC endonuclease in vivo and in vitro with DNA damage produced by antineoplastic anthracyclines.

B M Kacinski, W D Rupp.   

Abstract

The anthracycline antineoplastic agents Adriamycin and N-trifluoroacetyl-Adriamycin-14-valerate were assayed in vivo and in vitro for ability to produce DNA lesions recognized by the UVRABC endonuclease, a DNA repair enzyme of Escherichia coli which recognizes large, bulky lesions in DNA. We found that, while both drugs produce DNA lesions, only the lesions produced by Adriamycin were toxic. Hence, anthracycline antineoplastic activity may be related to production of large, bulky lesions in DNA, while toxicity may correlate with toxicity measured in a simple E. coli DNA repair mutant test system.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378370

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  The Streptomyces peucetius drrC gene encodes a UvrA-like protein involved in daunorubicin resistance and production.

Authors:  N Lomovskaya; S K Hong; S U Kim; L Fonstein; K Furuya; R C Hutchinson
Journal:  J Bacteriol       Date:  1996-06       Impact factor: 3.490

Review 2.  Nucleotide excision repair in Escherichia coli.

Authors:  B Van Houten
Journal:  Microbiol Rev       Date:  1990-03

3.  Survival of rat mammary tumor cell clones and DNA strand damage following adriamycin treatment.

Authors:  D P Evans; R E Meyn; S P Tomasovic
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Epidermal growth factor, phorbol esters, and aurintricarboxylic acid are survival factors for MDA-231 cells exposed to adriamycin.

Authors:  A Geier; R Beery; M Haimsohn; R Hemi; Z Malik; A Karasik
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-12       Impact factor: 2.416

Review 5.  A chemical perspective on the anthracycline antitumor antibiotics.

Authors:  B R Abdella; J Fisher
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.